vs
Side-by-side financial comparison of EGAIN Corp (EGAN) and Gossamer Bio, Inc. (GOSS). Click either name above to swap in a different company.
EGAIN Corp is the larger business by last-quarter revenue ($23.0M vs $13.8M, roughly 1.7× Gossamer Bio, Inc.). EGAIN Corp runs the higher net margin — 10.2% vs -342.3%, a 352.5% gap on every dollar of revenue. On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs 2.6%).
Headquartered in Sunnyvale, California, eGain Corporation helps businesses automate customer and employee experience with its AI knowledge software.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
EGAN vs GOSS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $13.8M |
| Net Profit | $2.3M | $-47.2M |
| Gross Margin | 73.1% | — |
| Operating Margin | 8.9% | -333.6% |
| Net Margin | 10.2% | -342.3% |
| Revenue YoY | 2.6% | 47.1% |
| Net Profit YoY | 248.1% | -43.0% |
| EPS (diluted) | $0.08 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $13.8M | ||
| Q3 25 | $23.5M | $13.3M | ||
| Q2 25 | $23.2M | — | ||
| Q1 25 | $21.0M | — | ||
| Q4 24 | $22.4M | — | ||
| Q3 24 | $21.8M | — | ||
| Q2 24 | $22.5M | $95.8M | ||
| Q1 24 | $22.4M | $0 |
| Q4 25 | $2.3M | $-47.2M | ||
| Q3 25 | $2.8M | $-48.2M | ||
| Q2 25 | $30.9M | — | ||
| Q1 25 | $66.0K | — | ||
| Q4 24 | $671.0K | — | ||
| Q3 24 | $652.0K | — | ||
| Q2 24 | $1.5M | $49.2M | ||
| Q1 24 | $1.5M | $-41.9M |
| Q4 25 | 73.1% | — | ||
| Q3 25 | 75.2% | — | ||
| Q2 25 | 72.7% | — | ||
| Q1 25 | 68.0% | — | ||
| Q4 24 | 70.2% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.3% | — | ||
| Q1 24 | 69.3% | — |
| Q4 25 | 8.9% | -333.6% | ||
| Q3 25 | 12.1% | -369.4% | ||
| Q2 25 | 14.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 5.3% | 54.3% | ||
| Q1 24 | 4.2% | — |
| Q4 25 | 10.2% | -342.3% | ||
| Q3 25 | 12.0% | -362.7% | ||
| Q2 25 | 132.8% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 6.7% | 51.4% | ||
| Q1 24 | 6.7% | — |
| Q4 25 | $0.08 | $-0.21 | ||
| Q3 25 | $0.10 | $-0.21 | ||
| Q2 25 | $1.09 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $0.05 | $0.22 | ||
| Q1 24 | $0.05 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $83.1M | $136.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.8M | $-122.8M |
| Total Assets | $146.8M | $172.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $83.1M | $136.9M | ||
| Q3 25 | $70.9M | $180.2M | ||
| Q2 25 | $62.9M | — | ||
| Q1 25 | $68.7M | — | ||
| Q4 24 | $70.5M | — | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $70.0M | $354.5M | ||
| Q1 24 | $83.0M | $244.4M |
| Q4 25 | $88.8M | $-122.8M | ||
| Q3 25 | $83.5M | $-82.3M | ||
| Q2 25 | $80.7M | — | ||
| Q1 25 | $51.6M | — | ||
| Q4 24 | $55.3M | — | ||
| Q3 24 | $55.7M | — | ||
| Q2 24 | $58.5M | $81.5M | ||
| Q1 24 | $63.9M | $26.7M |
| Q4 25 | $146.8M | $172.2M | ||
| Q3 25 | $144.6M | $208.8M | ||
| Q2 25 | $148.0M | — | ||
| Q1 25 | $106.2M | — | ||
| Q4 24 | $111.3M | — | ||
| Q3 24 | $114.9M | — | ||
| Q2 24 | $127.9M | $373.4M | ||
| Q1 24 | $120.3M | $259.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.1M | $-48.3M |
| Free Cash FlowOCF − Capex | $9.9M | — |
| FCF MarginFCF / Revenue | 43.0% | — |
| Capex IntensityCapex / Revenue | 1.0% | 0.0% |
| Cash ConversionOCF / Net Profit | 4.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | $17.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.1M | $-48.3M | ||
| Q3 25 | $10.4M | $-36.2M | ||
| Q2 25 | $-4.3M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $6.4M | — | ||
| Q3 24 | $954.0K | — | ||
| Q2 24 | $-5.1M | $116.3M | ||
| Q1 24 | $1.7M | $-52.3M |
| Q4 25 | $9.9M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $-4.5M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $6.3M | — | ||
| Q3 24 | $845.0K | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | $1.7M | — |
| Q4 25 | 43.0% | — | ||
| Q3 25 | 43.4% | — | ||
| Q2 25 | -19.5% | — | ||
| Q1 25 | 10.0% | — | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | -23.0% | — | ||
| Q1 24 | 7.8% | — |
| Q4 25 | 1.0% | 0.0% | ||
| Q3 25 | 1.0% | 0.0% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.2% | 0.0% | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 4.33× | — | ||
| Q3 25 | 3.70× | — | ||
| Q2 25 | -0.14× | — | ||
| Q1 25 | 33.48× | — | ||
| Q4 24 | 9.57× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -3.40× | 2.36× | ||
| Q1 24 | 1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EGAN
| Transferred Over Time | $22.0M | 96% |
| Technology Service | $1.2M | 5% |
GOSS
Segment breakdown not available.
